Analyst ratings, especially from reputable firms like Baird, can significantly influence investor perception and stock prices. An Outperform rating suggests that Baird expects Jazz Pharmaceuticals to perform better than the market or its sector, which could lead to increased investor interest and a potential rise in the stock price. The announcement of a price target of $160, which is presumably higher than the current trading price, indicates a bullish outlook on the stock, further supporting the potential for a positive short term impact.